No Data
Jiangsu Nhwa Pharmaceutical (002262.SZ) has obtained the "Pharmaceutical Registration Certificate" for Hydrobromide Vortioxetine Tablets.
Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the company recently obtained approval from the National Medical Products Administration.
Jiangsu Nhwa Pharmaceutical (002262.SZ): The company's fentanyl-related products have no export business.
Gelonghui, January 9 - Jiangsu Nhwa Pharmaceutical (002262.SZ) stated on the investor interaction platform that China's control over fentanyl products is relatively strict, and the company has no export business for its fentanyl products. The Trump administration's fentanyl policy is expected to have no adverse impact on the company's performance.
Retail Investors Are Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Biggest Owners and Were Hit After Market Cap Dropped CN¥813m
Jiangsu Nhwa Pharmaceutical (002262.SZ): Independent Director Academician Wang Guangji resigns.
On December 30, Gelonghui reported that Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the Board of Directors recently received a resignation letter from independent director Academician Wang Guangji, who, due to the need to comply with the regulations for part-time management stipulated in the 'Management Measures for Academicians of the Chinese Academy of Engineering,' applied to resign from his positions as independent director and member of the Board of Directors' Global Strategy Committee. After his resignation, Academician Wang Guangji will no longer hold any position in the company.
Jiangsu Nhwa Pharmaceutical Secures Approval for Mivacurium Chloride Injection
Is Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Stock's Recent Performance A Reflection Of Its Financial Health?
Little Excitement Around Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings
No Data
